Mark Casey - Mallinckrodt Plc Executive Vice President and Chief Legal Officer

MNKDelisted Stock  USD 0.34  0.00  0.00%   

President

Mr. Mark J. Casey is General Counsel of the Company since 2019.
Age 55
Tenure 5 years
Phone353 1 696 0000
Webhttps://www.mallinckrodt.com
Casey joined Mallinckrodt in February 2018. Before joining Mallinckrodt, Mr. Casey served as Senior Vice President, General Counsel, and Secretary of Idera Pharmaceuticals, Inc., a clinicalstage biopharmaceutical company, from June 2015 to January 2018. Prior to that, Mr. Casey served as Senior Vice President, Chief Administrative Officer, General Counsel, and Secretary at Hologic, Inc., a global medical device and diagnostics company, from March 2012 to December 2014 and as Senior Vice President, General Counsel, and Secretary from October 2007 to March 2012, following Hologic acquisition of Cytyc Corporationrationrationration. Prior to the acquisition, Mr. Casey served as Vice President, Deputy General Counsel, and Chief Patent Counsel of Cytyc from 2002 to 2007. Prior to joining Cytyc, Mr. Casey held roles of increasing responsibility at Boston Scientific Corporationration and EMC Corporationrationrationration.

Mallinckrodt Plc Management Efficiency

Mallinckrodt Plc's management efficiency ratios could be used to measure how well Mallinckrodt Plc manages its routine affairs as well as how well it operates its assets and liabilities.
The company has 3.07 B in debt with debt to equity (D/E) ratio of 1.44, which is OK given its current industry classification. Mallinckrodt Plc has a current ratio of 2.92, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Mallinckrodt Plc until it has trouble settling it off, either with new capital or with free cash flow. So, Mallinckrodt Plc's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Mallinckrodt Plc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Mallinckrodt to invest in growth at high rates of return. When we think about Mallinckrodt Plc's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 12 records

PRESIDENT Age

Parker JavidLifecore Biomedical
55
Andre JeromeAurora Cannabis
N/A
Carey SquiresAurora Cannabis
N/A
Todd WoodAlimera Sciences
54
Dave PatersonCanopy Growth Corp
N/A
Darren KarasiukAurora Cannabis
N/A
Steve DoblerAurora Cannabis
54
Marcie KiziakSNDL Inc
43
Jeffrey JacobsonCronos Group
38
Mike LeeCanopy Growth Corp
47
MD MBAShuttle Pharmaceuticals
55
Rade KovacevicCanopy Growth Corp
33
Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. The company was founded in 1867 and is based in Dublin, Ireland. Mallinckrodt Plc operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on AMEX Exchange. It employs 2778 people. Mallinckrodt Plc (MNK) is traded on NYSE MKT Exchange in USA and employs 2,673 people.

Management Performance

Mallinckrodt Plc Leadership Team

Elected by the shareholders, the Mallinckrodt Plc's board of directors comprises two types of representatives: Mallinckrodt Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mallinckrodt. The board's role is to monitor Mallinckrodt Plc's management team and ensure that shareholders' interests are well served. Mallinckrodt Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mallinckrodt Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
CPA CPA, Global Officer
David Norton, Independent Director
Hugh ONeill, Executive Vice President and President, Autoimmune and Rare Diseases
Steven Romano, Executive Vice President and Chief Scientific Officer
Sigurdur Olafsson, Pres CEO
Mark Trudeau, CEO and President Director and Member of Portfolio Committee
Kneeland Youngblood, Independent Director
Bryan Reasons, Chief Financial Officer, Executive Vice President
Mark Casey, Executive Vice President and Chief Legal Officer
JoAnn Reed, Independent Director
J Carroll, Independent Director
Lisa French, Ex Officer
Kassie Harrold, Ex Officer
Jason Goodson, Exec Devel
Ian Watkins, Chief Human Resource Officer, Executive Vice President
Stephen Welch, Ex Generics
Henriette Nielsen, Ex Officer
Steven MD, Ex Officer
Angus Russell, Independent Non-Executive Chairman of the Board
Paul Carter, Independent Director
Carlos Paya, Independent Director
Anne Whitaker, Independent Director
Mark Tyndall, Chief VP

Mallinckrodt Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mallinckrodt Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Mallinckrodt Plc in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Mallinckrodt Plc's short interest history, or implied volatility extrapolated from Mallinckrodt Plc options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Other Consideration for investing in Mallinckrodt Stock

If you are still planning to invest in Mallinckrodt Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Mallinckrodt Plc's history and understand the potential risks before investing.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Equity Valuation
Check real value of public entities based on technical and fundamental data
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Fundamental Analysis
View fundamental data based on most recent published financial statements
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum